This inventor holds 1 USPTO granted patent. Top assignee: Nexel Co., Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Jinhyuk Chang and Cardiac Safety Testing
Introduction
Jinhyuk Chang is an inventor based in Hanam-si, South Korea, and is associated with Nexel Co., Ltd. His work includes a patented method for evaluating the cardiac safety of drugs using cardiomyocytes derived from human stem cells.
Latest Patents
Chang is named on 1 patent: “Methods for Evaluating Cardiac Safety of Drug Using Cardiomyocytes Derived from Human Stem Cells.” The method prepares cardiomyocytes by differentiating human stem cells, uses fibronectin diluted in DPBS at a concentration of 50 μg/ml to prepare selected wells of a microelectrode array (MEA) plate, and adds a predetermined medium. It then measures changes in beat rate, spike amplitude, and field potential duration to assess the effects of a drug.
Career Highlights
Chang’s patent focuses on using human stem cell-derived cardiomyocytes and MEA measurements to evaluate drug-related cardiac effects. This approach provides a defined procedure for observing changes in electrical activity associated with drug exposure.
Collaborations
Chang is associated with Nexel Co., Ltd. His listed coworkers include Donghun Woo and Subin Kim.
Conclusion
Jinhyuk Chang’s patented method applies stem cell-derived cardiomyocytes and electrical measurements to drug cardiac safety evaluation.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile